Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study
Open Access
Abstract
Background: Hereditary angioedema (HAE) is an autosomal dominant inherited disease in which patients suffer from local attacks primarily affecting skin and gastrointestinal tract, and sometimes even the upper respiratory tract leading to asphyxiation. Since head‐to‐head trials between authorized treatments are lacking, this study compares efficacy and safety of lanadelumab and intravenous plasma‐derived C1‐esterase inhibitor (pdC1‐INH i.v.) in HAE patients on long‐term prophylaxis by means of an indirect treatment comparison.Methods: Efficacy and safety of lanadelumab against pdC1‐INH i.v. were analyzed in a fully prespecified indirect comparison based on individual patient data (n = 231) from the HELP and CHANGE clinical trials. Primary and secondary efficacy endpoints were compared using a generalized linear model for count data. Confounding variables were identified a priori via systematic literature research and validated by clinical experts. Adjustment of confounders was implemented using a conditional regression model.Results: Lanadelumab showed a statistically significant improvement in reduction of HAE attack rates compared to pdC1‐INH i.v. across multiple endpoints: Monthly attack rate of patients treated with lanadelumab was less than half compared to pdC1‐INH i.v. (Rate ratio: 0.486; 95% CI: 0.253, 0.932). Monthly rate of laryngeal attacks was found to be five times lower for lanadelumab (Rate ratio: 0.2; 95% CI: 0.044, 0.915) and monthly rate of acute treated HAE attacks among lanadelumab patients was about one third of the attack rate of pdC1‐INH i.v. patients (Rate ratio: 0.366; 95% CI: 0.185, 0.727).Conclusion: This study contributes to current knowledge in the treatment of HAE by indicating a statistically significant reduction of HAE attacks under lanadelumab compared to pdC1‐INH i.v.Keywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 18 references indexed in Scilit:
- The International/Canadian Hereditary Angioedema GuidelineAllergy, Asthma & Clinical Immunology, 2019
- Guideline: Hereditary angioedema due to C1 inhibitor deficiencyAllergo Journal, 2019
- Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema AttacksJAMA, 2018
- Methods for Population-Adjusted Indirect Comparisons in Health Technology AppraisalMedical Decision Making, 2017
- Depression and anxiety in patients with hereditary angioedemaAnnals of Allergy, Asthma & Immunology, 2014
- Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in EuropeOrphanet Journal of Rare Diseases, 2014
- Safety and Efficacy of Prophylactic Nanofiltered C1-inhibitor in Hereditary AngioedemaThe American Journal of Medicine, 2012
- Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness ResearchValue in Health, 2012
- Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary AngioedemaNew England Journal of Medicine, 2010
- Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and CourseThe American Journal of Medicine, 2006